|  | Aboriginal cohort | Matched non-Indigenous cohort |  |  | ||
---|---|---|---|---|---|---|---|
N | % | Â | Â | Odds Ratio (unadjusted) | 95%CI | ||
Total | Â | 777 | 100.0% | 777 | 100.0% | Â | Â |
Matching variables | |||||||
 Age | |||||||
  <50 years |  | 212 | 27.3% | 190 | 24.5% |  |  |
  50-69 years |  | 400 | 51.5% | 408 | 52.5% |  |  |
  70+ years |  | 165 | 21.2% | 179 | 23.0% |  |  |
 Sex | |||||||
  Male |  | 375 | 48.3% | 375 | 48.3% |  |  |
  Female |  | 402 | 51.7% | 402 | 51.7% |  |  |
 Primary site | |||||||
  Colorectal (C18-C21) |  | 77 | 9.9% | 77 | 9.9% |  |  |
  Lung (C33-C34) |  | 106 | 13.6% | 106 | 13.6% |  |  |
  Breast (C50 & Female) |  | 77 | 9.9% | 77 | 9.9% |  |  |
  Cervix (C53) |  | 24 | 3.1% | 24 | 3.1% |  |  |
  All other sites |  | 493 | 63.4% | 493 | 63.4% |  |  |
Socio-demographic and clinical variables | |||||||
 Geographically remote | |||||||
  No |  | 606 | 78.0% | 742 | 95.5% | 1.00 | Reference |
  Yes |  | 171 | 22.0% | 35 | 4.5% | 5.98 | 4.09-8.74 |
 Comorbid conditions (Elixhauser) | |||||||
  0-3 |  | 667 | 85.8% | 742 | 95.5% | 1.00 | Reference |
  4+ |  | 110 | 14.2% | 35 | 4.5% | 3.50 | 2.35-5.19 |
 Summary stage at diagnosis | |||||||
  Localised |  | 289 | 37.2% | 390 | 50.2% | 1.00 | Reference |
  Regional |  | 155 | 19.9% | 132 | 17.0% | 1.58 | 1.20-2.09 |
  Distant/Unstageable |  | 333 | 42.9% | 255 | 32.8% | 1.76 | 1.41-2.20 |
 Treatment modality | |||||||
  Hospitalisation with primary diagnosis of cancer | Received | 617 | 79.4% | 649 | 83.5% | 0.76 | 0.59-0.98 |
Not received | 160 | 20.6% | 128 | 16.5% | 1.00 | Reference | |
  Surgery | Received | 408 | 52.5% | 488 | 62.8% | 0.65 | 0.53-0.80 |
Not received | 369 | 47.5% | 289 | 37.2% | 1.00 | Reference | |
  Systemic therapy | Received | 252 | 32.4% | 334 | 43.0% | 0.64 | 0.52-0.78 |
Not received | 525 | 67.6% | 443 | 57.0% | 1.00 | Reference | |
  Radiotherapy | Received | 309 | 39.8% | 360 | 46.3% | 0.76 | 0.63-0.94 |
Not received | 468 | 60.2% | 417 | 53.7% | 1.00 | Reference | |
  Each of surgery, systemic and radiotherapy | Received | 77 | 9.9% | 140 | 18.0% | 0.50 | 0.37-0.67 |
Not received | 700 | 90.1% | 637 | 82.0% | 1.00 | Reference | |
  No surgery, systemic or radiotherapy | Received | 183 | 23.6% | 110 | 14.2% | 1.87 | 1.44-2.43 |
Not received | 594 | 76.4% | 667 | 85.8% | 1.00 | Reference | |
 Vital statusb | |||||||
  Alive |  | 220 | 28.3% | 349 | 44.9% | 1.00 | Reference |
  Cancer death |  | 461 | 59.3% | 340 | 43.8% | 2.15 | 1.73-2.68 |
  Non-cancer death |  | 96 | 12.4% | 88 | 11.3% | 1.73 | 1.24-2.42 |